By Ute Kilger, Patent Attorney, European Patent and Trade Mark Attorney, Boehmert & Boehmert Anwaltspartnerschaft mbB
The US Supreme Court has mutilated US Patent law with the law of nature doctrine created from the decisions Mayo v. Prometheus and AMP v. Myriad Genetics. Since then, the US-PTO has implemented guidelines, and the highest patent court in the US, the CAFC, has issued numerous decisions applying these Supreme Court decisions, making it hard or impossible to obtain useful patent protection and/or enforce it, in particular for inventions directed to diagnostic methods, or directed to naturally occurring substances.
3P Pharma finds new major investor
Latest NewsPamplona-based CDMO 3P Biopharmaceuticals (3P) has announced Keensight Capital as its new major investor after previous major investor Infarco is refocussing on international expansion. By providing 3P with leap in terms of capacity, equipment, technology, and talent, Keensight is expected to consolidate 3P’s position as one of few mid-sized CDMOs on the international market that offers commercial manufacturing capabilities.
"We are extremely enthusiastic to work with Keensight Capita at such a crucial moment for our industry," said Dámaso Molero, CEO of 3P Biopharmaceuticals. "With their global footprint and their expertise inthe biologics field, I am highly confident that Keensight team will help us reach significant milestones in the coming years.
3P experienced a 23% annual revenue growth over the past 4 years, 10% above the rate the biological CDMO market is to grow from 2018-2022. The fully integrated specialist in process development and GMP-compliant manufacturing biologics and cell therapy products is further being funded by Sodena, the financial business development instrument of the Government of Navarra.
Curetis lower respiratory tract panel ready for FDA clearance
Latest NewsMolecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.
Merck and Broad Institute announce CRISPR license agreement
Latest NewsMerck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.
IP Flash: Patent Ineligibility
OpinionBy Ute Kilger, Patent Attorney, European Patent and Trade Mark Attorney, Boehmert & Boehmert Anwaltspartnerschaft mbB
The US Supreme Court has mutilated US Patent law with the law of nature doctrine created from the decisions Mayo v. Prometheus and AMP v. Myriad Genetics. Since then, the US-PTO has implemented guidelines, and the highest patent court in the US, the CAFC, has issued numerous decisions applying these Supreme Court decisions, making it hard or impossible to obtain useful patent protection and/or enforce it, in particular for inventions directed to diagnostic methods, or directed to naturally occurring substances.
Controlled human malaria infection trials
BackgroundTackling the malaria pathogen P. falciparum has been complex, due to rapid development of resistance. A new compound targets liver stages of the parasite and, thus, provides a new mode of action to reduce the population of the parasite.
Billions for the circular economy
Latest NewsTogether with the EIB, five of the EU’s largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy.
Genmab launches US$502m IPO
Latest NewsDanish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
European Biotechnology Guide now available on app!
ProductsThe European Biotechnology Science & Industry Guide provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry, and is now also available as part of the BIOCOM app!
AM-Pharma raises €116m for Phase III
Latest NewsDutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase III.
US$5bn deal for Galapagos
Latest NewsBelgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform.